A Study of Bimatoprost 0.01% in the Clinical Setting
NCT01814761 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 312
Last updated 2015-10-26
Summary
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).
Conditions
- Glaucoma, Primary Open Angle
- Ocular Hypertension
Interventions
- DRUG
-
Bimatoprost 0.01%
One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
Sponsors & Collaborators
-
Allergan
lead INDUSTRY
Principal Investigators
-
Medical Director · Allergan
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2014-08-31
- Completion
- 2014-08-31
Countries
- Taiwan
Study Locations
More Related Trials
-
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
NCT01589510 ·Status: COMPLETED
-
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
NCT01628588 ·Status: COMPLETED
-
A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension
NCT01525173 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT01298700 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
NCT01863953 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension
NCT01157364 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
NCT01853085 ·Status: COMPLETED
-
Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution
NCT01001195 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)
NCT00716742 ·Status: COMPLETED
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma
NCT04890106 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
NCT01594970 ·Status: COMPLETED ·Phase: PHASE4
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
NCT05401357 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
NCT02061683 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
NCT06267274 ·Status: RECRUITING ·Phase: PHASE1
-
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
NCT01881126 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
NCT01243567 ·Status: COMPLETED ·Phase: PHASE4
-
24-hour IOP-lowering Effect of 0.01% Bimatoprost
NCT01271686 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
NCT01646151 ·Status: COMPLETED
-
Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma
NCT00487214 ·Status: COMPLETED
-
Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension
NCT02097719 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study
NCT04896125 ·Status: UNKNOWN
-
Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
NCT01068964 ·Status: COMPLETED ·Phase: NA
-
Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®
NCT01170884 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
NCT01830140 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
NCT00300443 ·Status: COMPLETED ·Phase: PHASE2/PHASE3